Immune T-cells of the CAR T-cell therapy CT103A are able to rapidly eliminate disease-driving immune cells and reduce immune cells’ overall inflammatory activity in people with neuromyelitis optica spectrum disorder (NMOSD), a study shows. “This study is the first in-depth single-cell … analysis of multiple types of body fluids…
CT103A CAR T-cells
The CAR T-cell therapy CT103A appears safe generally and may ease disability and improve the quality of life in adults with relapsed or refractory neuromyelitis optica spectrum disorder (NMOSD) who test positive for antibodies against aquaporin-4 (AQP4), according to data from a small Phase 1 clinical trial. “In this…
Recent Posts
- Immune cell traps may worsen NMOSD attacks, study finds
- Simple blood test may help guide personalized NMOSD treatment
- Life with NMOSD is a game I never asked to play, but keep winning
- Treatment linked to fewer NMOSD relapses, less steroid use in study
- Navigating NMOSD at the intersection of culture and family